Bavarian Nordic applies to EMA to use mpox vaccine in adolescents, FT reports

Bavarian Nordic (BVNRY) has applied to the European Medicines Agency to extend its mpox vaccine for use in 12 to 17-year-olds, and if successful, the vaccine could be approved for use among adolescents by the end of 2024, The Financial Times’ Ian Johnston reports. The World Health Organization declared a public health emergency over mpox on Wednesday and the first case of the new outbreak was reported in Sweden on Thursday. TheFly notes that Bavarian Nordic and Emergent BioSolutions (EBS) are the makers of the only two vaccines that the U.S. CDC currently recommends for mpox.